Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2019

15.05.2019 | Image of the Month

Retroperitoneal fibrosis in on-going anti-PD-1 immunotherapy detected with [18F]-FDG PET/CT

verfasst von: Aurélie Moreau, Anne Laure Giraudet, Thomas Mognetti, David Kryza

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Excerpt

A patient with metastatic lung adenocarcinoma was placed on immunotherapy with nivolumab. A first [ 18F]-FDG PET/CT examination was performed before immunotherapy ( a.). Two years after having initiated nivolumab, [ 18F]-FDG PET/CT showed an almost complete metabolic response, but revealed the occurrence of a hypermetabolic infiltration surrounding the abdominal artery and primary iliac arteries ( b., d.). This raised the potential diagnosis of retroperitoneal fibrosis (RPF) in the specific context of immunotherapy, although the assumptions of lymph node infiltration related to pulmonary adenocarcinoma, or lymphoproliferative syndrome, could not be eliminated. The histologic analysis confirmed the diagnosis of iatrogenic RPF. …
Literatur
2.
Zurück zum Zitat Fernández-López R, Lojo JA, Acevedo-Báñez I, González-León R, Borrego-Dorado I. (18)F-FDG PET/CT in patients with idiopathic retroperitoneal and mediastinal fibrosis. Eur J Nucl Med Mol Imaging. 2016;43(9):1739–40. CrossRefPubMed Fernández-López R, Lojo JA, Acevedo-Báñez I, González-León R, Borrego-Dorado I. (18)F-FDG PET/CT in patients with idiopathic retroperitoneal and mediastinal fibrosis. Eur J Nucl Med Mol Imaging. 2016;43(9):1739–40. CrossRefPubMed
3.
Zurück zum Zitat Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238–50. CrossRefPubMed Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238–50. CrossRefPubMed
4.
Zurück zum Zitat Fernando A, Pattison J, Horsfield C, D’Cruz D, Cook G, O’Brien T. [18F]-Fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. 2017;71(6):926–33. CrossRefPubMed Fernando A, Pattison J, Horsfield C, D’Cruz D, Cook G, O’Brien T. [18F]-Fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. 2017;71(6):926–33. CrossRefPubMed
Metadaten
Titel
Retroperitoneal fibrosis in on-going anti-PD-1 immunotherapy detected with [18F]-FDG PET/CT
verfasst von
Aurélie Moreau
Anne Laure Giraudet
Thomas Mognetti
David Kryza
Publikationsdatum
15.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04352-1

Weitere Artikel der Ausgabe 8/2019

European Journal of Nuclear Medicine and Molecular Imaging 8/2019 Zur Ausgabe